Experienced in Ewing Sarcoma

Dr. Neil E. Faulkner

Hematology Oncology | Hematology | Oncology
University Health System, Inc.
1926 Alcoa Hwy 410, 
Knoxville, TN 
Accepting New Patients
Offers Telehealth
Experienced in Ewing Sarcoma
University Health System, Inc.
1926 Alcoa Hwy 410, 
Knoxville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Neil Faulkner is a Hematologist Oncology specialist and a Hematologist in Knoxville, Tennessee. Dr. Faulkner is rated as an Experienced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). Dr. Faulkner is currently accepting new patients.

His clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MI
Hospital Affiliations
University Health System, Inc
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

UNIVERSITY HEALTH SYSTEM, INC.
1926 Alcoa Hwy 410, Knoxville, TN 37920

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug
Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK
Study Phase: Phase 2
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
Enrollment Status: Terminated
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Trilaciclib, Docetaxel
Study Phase: Phase 2
A Phase 2a Open-Label Trial of the Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis in Subjects Receiving Chemoradiotherapy for Lung Cancer
A Phase 2a Open-Label Trial of the Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis in Subjects Receiving Chemoradiotherapy for Lung Cancer
Enrollment Status: Terminated
Publish Date: March 23, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 2
View 5 Less Clinical Trials
Similar Doctors
Experienced in Ewing Sarcoma
Dr. Dharmen J. Patel
Hematology Oncology | Hematology | Oncology
Experienced in Ewing Sarcoma
Dr. Dharmen J. Patel
Hematology Oncology | Hematology | Oncology

Tennessee Cancer Specialists PLLC

900 E Hill Ave, Suite 230, 
Knoxville, TN 
 (3.0 miles away)
Languages Spoken:
English, Bengali, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Dharmen Patel is a Hematologist Oncology specialist and a Hematologist in Knoxville, Tennessee. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Penile Cancer, Hemochromatosis, Non-Hodgkin Lymphoma, and Acute Mountain Sickness. Dr. Patel is currently accepting new patients.

Experienced in Ewing Sarcoma
Dr. Nathan E. Schrock
Hematology Oncology | Hematology | Oncology
Experienced in Ewing Sarcoma
Dr. Nathan E. Schrock
Hematology Oncology | Hematology | Oncology

University Health System, Inc.

1926 Alcoa Hwy 410, 
Knoxville, TN 
 (0.1 miles away)
865-544-9218
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nathan Schrock is a Hematologist Oncology specialist and a Hematologist in Knoxville, Tennessee. Dr. Schrock is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Childhood Iron Deficiency Anemia, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Iron Deficiency Anemia. Dr. Schrock is currently accepting new patients.

Experienced in Ewing Sarcoma
Dr. Yi I. Feng
Hematology Oncology | Oncology | Hematology
Experienced in Ewing Sarcoma
Dr. Yi I. Feng
Hematology Oncology | Oncology | Hematology

Tennessee Cancer Specialists PLLC

7650 Dannaher Dr, Suite 100, 
Powell, TN 
 (8.6 miles away)
865-637-9330
Experience:
43+ years
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Yi Feng is a Hematologist Oncology specialist and an Oncologist in Powell, Tennessee. Dr. Feng has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Iron Deficiency Anemia, Breast Cancer, Pleuropulmonary Blastoma, and Colorectal Cancer. Dr. Feng is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Faulkner's expertise for a condition
ConditionClose
    View All 20 Advanced Conditions
    View All 74 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile